New tricks.

The article discusses the use of interleukin-2 in the cancer drug development efforts of researcher Floyd Romesberg and colleagues in collaboration with biotechnology firm Synthorx. Topics explored include the use of semisynthetic cells by the researchers to expand the genetic code, the anti-tumour...

Descripción completa

Detalles Bibliográficos
Publicado en:Economist Vol. 430; no. 9126; pp. 76 - 78
Formato: Artículo
Publicado: Economist Newspaper Limited 1/19/2019
Materias:
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ssf&AN=134259858&site=ehost-live
header:
  @attributes:
    shortDbName: ssf
    uiTerm: 134259858
    longDbName: Social Sciences Full Text (H.W. Wilson)
    uiTag: AN
  controlInfo:
    bkinfo:
    jinfo:
      jid:
        00130613
        ECO
      jtl: Economist
      issn: 00130613
      maglogo: N
    pubinfo:
      dt: 1/19/2019
      vid: 430
      iid: 9126
      pid: 161
      pub: Economist Newspaper Limited
    artinfo:
      ui: 134259858
      ppf: 76
      ppct: 2
      formats:
      tig:
        atl: New tricks.
      aug:
      su:
        Synthorx Inc.
        Interleukin-2
        Antineoplastic agent development
        Cancer treatment
        Drug development
        Pharmaceutical research
        Genetic code
      sug:
        subj:
          Synthorx Inc.
          Pharmaceutical and medicine manufacturing
          Pharmaceuticals and pharmacy supplies merchant wholesalers
          Drugs and Druggists' Sundries Merchant Wholesalers
          Research and development in the physical, engineering and life sciences
          Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
          Interleukin-2
          Antineoplastic agent development
          Cancer treatment
          Drug development
          Pharmaceutical research
          Genetic code
      ab: The article discusses the use of interleukin-2 in the cancer drug development efforts of researcher Floyd Romesberg and colleagues in collaboration with biotechnology firm Synthorx. Topics explored include the use of semisynthetic cells by the researchers to expand the genetic code, the anti-tumour response associated with interleukin-2, and the bond between interleukin-2 and immune cells.
      pubtype: Periodical
      doctype: Article
      src: R
    language: English
    refInfo:
    copyright:
      @attributes:
        flag: N
    holdings:
      @attributes:
        islocal: N